Factors associated with daptomycin consumption in French hospitals between 2019 and 2020: A nationwide surveillance study.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 27 09 2022
revised: 25 11 2022
accepted: 02 12 2022
pubmed: 13 12 2022
medline: 9 3 2023
entrez: 12 12 2022
Statut: ppublish

Résumé

This study aimed to investigate factors associated with daptomycin consumption in French healthcare facilities (HCF) between 2019 and 2020. Antibiotic consumption expressed as number of defined daily doses (DDD) per 1,000 patient-days (PD) and antimicrobial resistance (AMR) expressed as incidence densities per 1,000PD were extracted each year from the nationwide surveillance network run by the SPARES project (Surveillance and Prevention of Antimicrobial RESistance in hospitals), collecting data at ward level among voluntary HCFs using standardized methodology and webtool. All HCF participating both in 2019 and 2020 were included. A multivariable linear regression was fitted. Among 622 HCFs, we analyzed daptomycin consumption and AMR data in 1,637 clinical wards. Incidence densities of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCNS) were the highest in intensive care unit wards (0.54 and 6.83 respectively in 2020). On the most adjusted model, the year 2020 was correlated with a higher daptomycin consumption (1.53; p = 0.01). A greater number of inpatient beds (0.01; p < 0.001), the presence of orthopedic surgery activity in the HCF (1.66; p < 0.02), MRSA (4.38; p < 0.001) and MRCNS (0.61; p < 0.001) incidence densities were associated with a higher daptomycin use. The final model explained 18% of the observed variance. This study showed that daptomycin consumption was correlated to MRSA and MRCNS incidence densities, to the year 2020 and to non-modifiable HCF-related factors. Prevention of coagulase-negative staphylococci infections should be considered by antimicrobial stewardship teams when daptomycin use is going up in HCF.

Identifiants

pubmed: 36503170
pii: S2666-9919(22)00274-3
doi: 10.1016/j.idnow.2022.12.001
pii:
doi:

Substances chimiques

Daptomycin NWQ5N31VKK
Coagulase 0
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104636

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

A Loffler (A)

CHU Bordeaux GH Pellegrin, Centre d'appui pour la Prévention des Infections Associées aux Soins, Nouvelle-Aquitaine, Bordeaux, France. Electronic address: adamloffler@outlook.fr.

A-G Venier (AG)

CHU Bordeaux GH Pellegrin, Centre d'appui pour la Prévention des Infections Associées aux Soins, Nouvelle-Aquitaine, Bordeaux, France.

A Jouzeau (A)

CHRU de Nancy, Centre d'appui pour la Prévention des Infections Associées aux Soins, Grand-Est, Hôpitaux de Brabois, Nancy, France.

M Péfau (M)

CHU Bordeaux GH Pellegrin, Centre d'appui pour la Prévention des Infections Associées aux Soins, Nouvelle-Aquitaine, Bordeaux, France.

L Dugravot (L)

CHRU de Nancy, Centre d'appui pour la Prévention des Infections Associées aux Soins, Grand-Est, Hôpitaux de Brabois, Nancy, France.

A Chabaud (A)

CHU Dupuytren, Centre d'appui pour la Prévention des Infections Associées aux Soins, Nouvelle-Aquitaine, Limoges, France.

L Simon (L)

CHRU de Nancy, Centre d'appui pour la Prévention des Infections Associées aux Soins, Grand-Est, Hôpitaux de Brabois, Nancy, France.

C Dumartin (C)

CHU Bordeaux GH Pellegrin, Centre d'appui pour la Prévention des Infections Associées aux Soins, Nouvelle-Aquitaine, Bordeaux, France; Univ. Bordeaux, INSERM, BPH, AHeaD Team, U1219, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH